Relief Therapeutics Advances Publication of 2025 Half-Year Report
The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
SOURCE: Relief Therapeutics Holding SA
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Compass Therapeutics Announces Proposed Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ('Compass') (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the 'SEC') on August 30, 2024 and declared effective by the SEC on September 6, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Piper Sandler & Co. by mail at 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401 or by email at prospectus@ and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. Forward-Looking Statements Various statements in this release concerning the timing, size, structure and completion of the proposed public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Compass's control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Compass's stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled 'Risk Factors' in the prospectus supplement and registration statement referenced above and in Compass's Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025, and subsequent reports with the SEC. There can be no assurance that Compass will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Compass undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contactir@ ContactAnna Gifford, Chief of Staffmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Okeanis Eco Tankers Corp. – Key Information relating to Q2 2025 dividend
ATHENS, Greece, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. ('OET' or the 'Company') (NYSE: ECO / OSE: OET) announced today that the Company's board of directors (the 'Board') has declared a dividend on its common shares (the 'Dividend'). Due to implementation of the Central Securities Depository Regulation ('CSDR') in Norway, shareholders who hold common shares registered in Euronext Securities Oslo, the central securities depository in Norway ('VPS') should please note the information on the payment date to the common shares registered in VPS below. The New York Stock Exchange ('NYSE') settles its trades on a T+1 basis, while the Oslo Stock Exchange ('OSE') settles its trades on a T+2 basis. As a result, there will be different ex-dividend dates between the two exchanges, as set out below. Key information relating to the Dividend: Dividend amount: USD 0.70 per common share. Declared currency: USD. Dividends payable to common shares registered in the Euronext VPS will be distributed in NOK. Date of Board approval: August 12, 2025. Last day including right OSE: August 20, 2025, the last date on which the Company's common shares trading on the OSE will include the entitlement to the Dividend. Last day including right NYSE: August 21, 2025, the last date on which the Company's common shares trading on the NYSE will include the entitlement to the Dividend. Ex-date OSE: August 21, 2025, the date on which the Company's common shares will begin trading on the OSE without the entitlement to the Dividend. Ex-date NYSE: August 22, 2025, the date on which the Company's common shares will begin trading on the NYSE without the entitlement to the Dividend. Record date OSE and NYSE: August 22, 2025 Payment date: September 5, 2025. Due to the implementation of CSDR in Norway, the Dividend payable on common shares that are registered in the Euronext VPS is expected to be distributed to Euronext VPS shareholders on or about September 10, 2025. The Company encourages you to contact your bank, broker, nominee or other institution if you have any questions regarding the mechanics and timing of having the Dividend attributable to your common shares credited to your account. Contacts Company:Iraklis Sbarounis, CFOTel: +30 210 480 4200ir@ Investor Relations / Media Contact:Nicolas Bornozis, PresidentCapital Link, Inc.230 Park Avenue, Suite 1540, New York, N.Y. 10169Tel: +1 (212) 661-7566okeanisecotankers@ About OET OET is a leading international tanker company providing seaborne transportation of crude oil and refined products. The Company was incorporated on April 30, 2018 under the laws of the Republic of the Marshall Islands and is listed on Oslo Stock Exchange under the symbol OET and the New York Stock Exchange under the symbol ECO. The sailing fleet consists of six modern scrubber-fitted Suezmax tankers and eight modern scrubber-fitted VLCC tankers. Forward-Looking Statements This communication contains 'forward-looking statements', including as defined under U.S. federal securities laws. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as 'anticipate,' 'believe,' 'continue,' 'estimate,' 'expect,' 'hope,' 'intend,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will' or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including as described in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'). Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Factors that could cause actual results to differ materially include, but are not limited to, the Company's operating or financial results; the Company's liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations; broader market impacts arising from war (or threatened war) or international hostilities; risks associated with pandemics, including effects on demand for oil and other products transported by tankers and the transportation thereof; and other factors listed from time to time in the Company's filings with the SEC. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. You should, however, review the factors and risks the Company describes in the reports it files and furnishes from time to time with the SEC, which can be obtained free of charge on the SEC's website at This information is published in accordance with the requirements of the Continuing in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Why TPI Composites (TPIC) Stock Is Trading Lower Today
What Happened? Shares of global wind blade manufacturer TPI Composites (NASDAQ:TPIC) fell 40.6% in the afternoon session after the company filed for Chapter 11 bankruptcy protection to pursue a comprehensive financial restructuring. The company initiated voluntary Chapter 11 proceedings to address significant financial challenges, including over $1 billion in debt. To support its operations during this period, TPI has secured up to $82.5 million in financing from its senior lender, Oaktree Capital Management, which is now expected to take over the company. The filing follows a weak second-quarter report where revenue of $276.2 million missed analyst forecasts. TPI Composites warned that its common stock is highly speculative, expecting that shareholders will not receive any distributions and that the equity will likely be canceled and delisted from the Nasdaq exchange. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy TPI Composites? Access our full analysis report here, it's free. What Is The Market Telling Us TPI Composites's shares are extremely volatile and have had 107 moves greater than 5% over the last year. But moves this big are rare even for TPI Composites and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 22 days ago when the stock dropped 4.5% as investors anticipated a busy week of corporate earnings. There was no significant company-specific news to explain the move for the wind blade manufacturer, suggesting its shares were lifted by positive market sentiment. U.S. stock futures indicated a higher open for the markets, setting an upbeat tone for investors who were anticipating a heavy slate of earnings reports from major U.S. companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. TPI Composites is down 90.6% since the beginning of the year, and at $0.17 per share, it is trading 96.6% below its 52-week high of $4.92 from October 2024. Investors who bought $1,000 worth of TPI Composites's shares 5 years ago would now be looking at an investment worth $5.56. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
